Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
2.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2018 Sep 29;104:1-8. doi: 10.1016/j.ejca.2018.07.011. [Epub ahead of print]

PMID:
30278378
3.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

4.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

5.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.

PMID:
29217526
6.

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.

J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.

7.

Immunotherapy-based combinations: current status and perspectives.

de Miguel-Luken MJ, Mansinho A, Boni V, Calvo E.

Curr Opin Oncol. 2017 Sep;29(5):382-394. doi: 10.1097/CCO.0000000000000391.

PMID:
28678031
8.

The future of oncology therapeutics.

Mansinho A, Boni V, de Miguel M, Calvo E.

Expert Rev Anticancer Ther. 2017 Jul;17(7):563-565. doi: 10.1080/14737140.2017.1331131. Epub 2017 May 22. No abstract available.

PMID:
28504011
9.

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J.

Sci Rep. 2017 Jan 24;7:41371. doi: 10.1038/srep41371.

10.

Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.

Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E.

Invest New Drugs. 2017 Apr;35(2):198-206. doi: 10.1007/s10637-016-0410-3. Epub 2016 Nov 21.

PMID:
27873130
11.

Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.

Calvo E, Reddy G, Boni V, García-Cañamaque L, Song T, Tjornelund J, Choi MR, Allen LF.

Invest New Drugs. 2016 Apr;34(2):193-201. doi: 10.1007/s10637-015-0321-8. Epub 2016 Jan 14.

PMID:
26769244
12.

Skeletal muscle metaboreflex in patients with chronic renal failure.

Vieira PJ, Silva LR, Maldamer VZ, Cipriano G Jr, Chiappa AM, Schuster R, Boni VH, Grandi T, Wolpat A, Roseguini BT, Chiappa GR.

Clin Physiol Funct Imaging. 2017 Mar;37(2):229-234. doi: 10.1111/cpf.12293. Epub 2015 Aug 24.

PMID:
26303148
13.

[¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.

Marti-Climent JM, Dominguez-Prado I, Garcia-Velloso MJ, Boni V, Peñuelas I, Toledo I, Richter JA.

Rev Esp Med Nucl Imagen Mol. 2014 Sep-Oct;33(5):280-5. doi: 10.1016/j.remn.2014.01.007. Epub 2014 Jul 23.

14.

Coronary artery disease screening in type II diabetic patients: prognostic value of rest and stress echocardiography.

Innocenti F, Bartalucci F, Boni V, Vicidomini S, Mannucci E, Monami M, Pini R.

Diabetes Metab Syndr. 2014 Jan-Mar;8(1):18-23. doi: 10.1016/j.dsx.2013.10.010. Epub 2013 Nov 14.

PMID:
24661753
15.

Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging.

Etxano J, García-Lallana Valbuena A, Antón Ibáñez I, Elizalde A, Pina L, García-Foncillas J, Boni V.

Radiologia. 2015 Jan-Feb;57(1):44-9. doi: 10.1016/j.rx.2013.01.006. Epub 2014 Feb 10. English, Spanish.

16.

Prognostic value of emergency physician performed echocardiography in patients with acute pulmonary thromboembolism.

Zanobetti M, Converti C, Conti A, Viviani G, Guerrini E, Boni V, Vicidomini S, Poggioni C, Guzzo A, Coppa A, Bigiarini S, Innocenti F, Pini R.

West J Emerg Med. 2013 Sep;14(5):509-17. doi: 10.5811/westjem.2013.4.12690.

17.

Clinical management of atrial fibrillation: early interventions, observation, and structured follow-up reduce hospitalizations.

Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V, Pini R, Vanni S, Padeletti L, Gensini GF.

Am J Emerg Med. 2012 Nov;30(9):1962-9. doi: 10.1016/j.ajem.2012.04.022. Epub 2012 Jul 15.

PMID:
22795994
18.

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.

Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, Zarate R, Bandres E, Garcia-Foncillas J.

Br J Cancer. 2012 Jul 10;107(2):287-90. doi: 10.1038/bjc.2012.242. Epub 2012 Jun 14.

19.

Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.

Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, Rodriguez J, Bandres E, Garcia-Foncillas J.

World J Gastroenterol. 2012 Feb 21;18(7):637-45. doi: 10.3748/wjg.v18.i7.637.

20.

MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer?

Zarate R, Boni V, Bandres E, Garcia-Foncillas J.

Int J Mol Sci. 2012;13(1):840-65. doi: 10.3390/ijms13010840. Epub 2012 Jan 16. Review.

21.

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

Rodríguez J, Zarate R, Bandres E, Boni V, Hernández A, Sola JJ, Honorato B, Bitarte N, García-Foncillas J.

Eur J Cancer. 2012 Aug;48(12):1774-80. doi: 10.1016/j.ejca.2012.01.007. Epub 2012 Feb 2.

PMID:
22305465
22.

MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P, Garcia-Foncillas J.

Stem Cells. 2011 Nov;29(11):1661-71. doi: 10.1002/stem.741.

23.

Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.

Rodriguez J, Boni V, Hernández A, Bitarte N, Zarate R, Ponz-Sarvisé M, Chopitea A, Bandres E, Garcia-Foncillas J.

Eur J Cancer. 2011 Apr;47(6):839-47. doi: 10.1016/j.ejca.2010.11.032. Epub 2011 Jan 8.

PMID:
21220199
24.

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.

Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J.

Br J Cancer. 2010 Nov 9;103(10):1529-35. doi: 10.1038/sj.bjc.6605908. Epub 2010 Oct 12.

25.

miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.

Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E.

Mol Cancer Ther. 2010 Aug;9(8):2265-75. doi: 10.1158/1535-7163.MCT-10-0061. Epub 2010 Jul 20.

26.

Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.

Boni V, Zarate R, Villa JC, Bandrés E, Gomez MA, Maiello E, Garcia-Foncillas J, Aranda E.

Pharmacogenomics J. 2011 Dec;11(6):429-36. doi: 10.1038/tpj.2010.58. Epub 2010 Jun 29.

PMID:
20585341
27.

Strength of correlation effects in the electronic structure of iron.

Sánchez-Barriga J, Fink J, Boni V, Di Marco I, Braun J, Minár J, Varykhalov A, Rader O, Bellini V, Manghi F, Ebert H, Katsnelson MI, Lichtenstein AI, Eriksson O, Eberhardt W, Dürr HA.

Phys Rev Lett. 2009 Dec 31;103(26):267203. Epub 2009 Dec 23.

PMID:
20366340
28.

The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Braccini G, Festini F, Boni V, Neri AS, Galici V, Campana S, Zavataro L, Trevisan F, Braggion C, Taccetti G.

J Chemother. 2009 Apr;21(2):188-92.

PMID:
19423472
29.

Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.

Braccini G, Lori I, Neri AS, Festini F, Pela I, Ciuti R, Boni V, Zavataro L, Braggion C, De Martino M, Taccetti G.

J Chemother. 2009 Feb;21(1):101-4. No abstract available.

PMID:
19297282
30.

MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer.

Boni V, Bandres E, Zarate R, Colucci G, Maiello E, Garcia-Foncillas J.

Oncology. 2009;77 Suppl 1:75-89. doi: 10.1159/000258499. Epub 2010 Feb 2. Review.

PMID:
20130435
31.

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis.

Taccetti G, Campana S, Neri AS, Boni V, Festini F.

J Chemother. 2008 Apr;20(2):166-9. Review.

PMID:
18467240
32.

Features of apoptosis in Plasmodium falciparum erythrocytic stage through a putative role of PfMCA1 metacaspase-like protein.

Meslin B, Barnadas C, Boni V, Latour C, De Monbrison F, Kaiser K, Picot S.

J Infect Dis. 2007 Jun 15;195(12):1852-9. Epub 2007 May 7.

PMID:
17492602
34.

[Pathophysiology of pancreatico-duodenectomy according to Traverso-Longmire. Clinical and instrumental study].

Agresta F, Trentin G, Michelet I, Pintaldi S, Conigliaro S, Boni V, Tonietto G.

Minerva Chir. 1994 Oct;49(10):907-11. Italian.

PMID:
7808663
35.

[Pancreatoduodenectomy using the Traverso-Longmire technique in the surgical treatment of carcinoma of the pancreas and periampullary region. Our experience].

Valerio S, Boni V, Conigliaro S, Michelet I, Trentin G, Tonietto G.

Minerva Chir. 1991 Mar 31;46(6):247-50. Italian.

PMID:
1646424
36.

[Aneurysm of the hand as an unusual complication of occupational injury].

Agus GB, Bonalumi F, Boni V, Carlesi R, Domanin M.

Med Lav. 1987 May-Jun;78(3):235-8. Italian. No abstract available.

PMID:
3657693
37.

The repair of lesions of the extensor tendons of the thumb.

Boni V.

Panminerva Med. 1968 Apr;10(4):140-51. No abstract available.

PMID:
5658697
38.

[Pathogenesis of meniscal calcifications].

Boni V, Dominici C.

Arch Putti Chir Organi Mov. 1968;23:433-40. Italian. No abstract available.

PMID:
5732111
39.

[The problem of anesthesia in congenital dislocation of the hip].

Di Pierro A, Boni V.

Arch Putti Chir Organi Mov. 1968;23:377-83. Italian. No abstract available.

PMID:
5732106
40.

[Arthrodesis of the hip. (Long-term follow-up of anatomo-functional results)].

CALANDRIELLO B, BONI V.

Arch Putti Chir Organi Mov. 1962;16:121-5. Italian. No abstract available.

PMID:
14017800
41.

[Etiopathogenetic, clinical and radiographic considerations on Ribbing's disease. (Report of 2 cases of familial nature)].

BETTINI G, BONI V.

Arch Putti Chir Organi Mov. 1962;16:58-72. Italian. No abstract available.

PMID:
13967845
42.
43.

The management of orthopaedic problems in haemophiliacs. A review of 21 cases.

CROCK HV, BONI V.

Br J Surg. 1960 Jul;48:8-15. No abstract available.

PMID:
13696516
44.

[Structure of epiphyseal tendon insertion].

THURNER J, BONI V.

Zentralbl Allg Pathol. 1958 May 31;97(10-11):534-8. German. No abstract available.

PMID:
13582005
45.

[Clinical manifestations, pathogenesis & treatment of calcaneal spurs].

THURNER J, BONI V.

Z Orthop Ihre Grenzgeb. 1957;89(2):161-79. German. No abstract available.

PMID:
13496957

Supplemental Content

Support Center